SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 197.01-2.9%Dec 1 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (4297)7/26/1997 12:38:00 AM
From: Andrew H   of 32384
 
>>However, I do not believe that the trial was blind. I think it was open label and each patient would serve as a control (glucose, insulin, and triglyceride levels would be monitored and compared to baseline values). The purpose of this small trial was to identify the most effective dose and provide preliminary data.<<

Ah, so.

>>I'm not sure when the first and last patient was enrolled, but I would suspect that LGND has some preliminary data already (although the Rezulin data improved as the time on that drug approached 120 days)<<.

So if we assume it took about 2months? to full enrollment, trial should be completely over by Sept. 20, but some have already finished. Sounds like analysis of results shouldn't take too long.

>>For all of the Rezulin data I have uploaded (except for FDA appoval), you can substitute Targretin for Rezulin and RXR for PPAR and re-read each article.<<

Pretty confident, eh? Why do we have to leave out FDA approval? (:>)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext